IDEAYA Biosciences
Bookmark
ShareIDEAYA Biosciences is a company. It is located in South San Francisco, the United States and was founded in 2015. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: South San Francisco
- state: CA
- country: United States
- sector: Health Care
- industry: Biotechnology
- foundation year: 2015
- CEO: Yujiro S. Hata
- CEO gender: Male
Classified as: organization
Business
IDEAYA Biosciences is one of the companies in the United States, companies in Biotechnology, companies in Health Care and 3,550,070 companies in our database.
- Assets: 381.3M $
- Debt: 4.4M $
- Employees: 91 people
- Free cash flow: -9123620 $
- Market cap: 365.5M $
- Revenues: 29.1M $
Stocks from IDEAYA Biosciences:
Talking Points
- IDEAYA Biosciences
- 51-200 employees Headquarters South San Francisco, California Type Public Company Founded 2015 Specialties Synthetic Lethality and Precision Medicine Locations Primary 7000 Shoreline Court 350...
- IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I
- II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and
- or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I
- II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Learn more about talking points
